News

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...
Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...
Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...
Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...
Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...
Pfizer was among the 17 companies that received a July 31 letter from president Donald Trump demanding lower drug prices. Pfizer maintained its full-year revenue forecast, but raised its full-year ...
Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...